Good conservative summary about ipilimumab, braf inhibitors and ckit inhibitors.
New and emerging approaches to the treatment of melanoma are described by Daniel G. Coit, MD, from Memorial Sloan-Kettering Cancer Center in this video from the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care for cancer patients. For more information on melanoma and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com.
Until three years ago these were our only treatment options. We have come a long way baby. But this is a good overview of the past preferred treatment options.
Vemurafenib (brand name Zelboraf) NEW DISCOVERY
New research on mice shows that drug-resistant melanoma tumors shrink when treatment is interrupted, or given a "holiday", suggesting that altering the dose pattern of cancer drug treatment in this manner could be a simple way to extend survival in human patients with late-stage disease. However, only human trials can verify if this is the case.
Co-lead researcher Martin McMahon, a cancer biologist at UCSF, and colleagues, found that one mechanism by which melanoma cancer cells become resistant to the anti-cancer drug vemurafenib (brand name Zelboraf), also makes them become addicted to it.
The consequence of this simultaneous resistance-cum-addiction to vemurafenib is that the cancer cells then proceed to use the compound to boost the growth of deadly, fast growing, drug-resistant tumors.
Once they made this discovery the team proceeded to experiment with changing patterns of drug dosage to see what effect this might have on mice implanted with melanoma tumors.
Drug combinatorial screening was used to identify effective combinations for mutant BRAF melanomas, including those resistant to vemurafenib, and mutant RAS melanomas that are resistant to many therapies.